OnKure Therapeutics (OKUR) Interest Expenses (2020 - 2026)
OnKure Therapeutics' (OKUR) quarterly Interest Expenses came in at $145000.0 in Q1 2026, up 3.57% YoY from $140000.0 in Q1 2025, and up 0.69% on a QoQ basis from $144000.0 in Q4 2025.
OnKure Therapeutics (OKUR) Interest Expenses (2020 - 2026) Analysis & Trends
OnKure Therapeutics (OKUR) has 7 years of Interest Expenses data on file, last reported at $145000.0 in Q1 2026.
- Quarterly Interest Expenses rose 3.57% year-over-year to $145000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $635000.0 (up 114.53% YoY) and the FY2025 annual result came in at $571000.0, down 99.37% from the prior year.
- Interest Expenses climbed to $145000.0 in Q1 2026, from $144000.0 in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $19.2 million in Q3 2023 to a low of -$103000.0 in Q4 2023.
- A 5-year average of $3.0 million and a median of $379000.0 in 2022 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 3032.98% in 2023, down 200.0% in 2023.
- Tracing OKUR's Interest Expenses over 5 years: stood at $103000.0 in 2022, then slumped by 200.0% to -$103000.0 in 2023, then jumped by 300.0% to $206000.0 in 2024, then slumped by 30.1% to $144000.0 in 2025, then increased by 0.69% to $145000.0 in 2026.
- The last three Interest Expenses figures came in at $145000.0 (Q1 2026), $144000.0 (Q4 2025), and $705000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | OnKure Therapeutics | 195.74 Mn | 19.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 836,000.00 |
| Jun 30, 2026 | 836,000.00 |
| Mar 31, 2026 | 145,000.00 |
| Mar 31, 2026 | 145,000.00 |
| Dec 31, 2025 | 144,000.00 |
| Dec 31, 2025 | 144,000.00 |
| Sep 30, 2025 | 705,000.00 |
| Sep 30, 2025 | 705,000.00 |
| Jun 30, 2025 | 849,000.00 |
| Jun 30, 2025 | 849,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Mar 31, 2025 | 140,000.00 |
| Dec 31, 2024 | 206,000.00 |
| Dec 31, 2024 | 206,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Sep 30, 2024 | 89,000.00 |
| Jun 30, 2024 | 851,000.00 |
| Jun 30, 2024 | 851,000.00 |
| Mar 31, 2024 | 53,000.00 |
| Mar 31, 2024 | 53,000.00 |